Simply Wall St
4 min read
As global markets navigate a mixed landscape marked by the end of the longest U.S. government shutdown and cautious monetary policy signals, Asian tech stocks present intriguing opportunities amidst these shifting dynamics. With small-cap stocks showing sensitivity to interest rate movements, identifying high-growth tech companies in Asia requires a keen focus on innovation potential and resilience to broader economic pressures.
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Accton Technology | 21.66% | 24.66% | ★★★★★★ |
| Giant Network Group | 33.47% | 39.54% | ★★★★★★ |
| Suzhou TFC Optical Communication | 34.61% | 35.52% | ★★★★★★ |
| Shengyi TechnologyLtd | 21.50% | 32.87% | ★★★★★★ |
| Zhongji Innolight | 31.35% | 32.09% | ★★★★★★ |
| Fositek | 37.73% | 51.15% | ★★★★★★ |
| Gold Circuit Electronics | 25.30% | 31.13% | ★★★★★★ |
| ISU Petasys | 22.15% | 34.79% | ★★★★★★ |
| eWeLLLtd | 25.02% | 24.93% | ★★★★★★ |
| CARsgen Therapeutics Holdings | 100.40% | 118.16% | ★★★★★★ |
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medy-Tox Inc. is a South Korean biopharmaceutical company with a market cap of ₩891.46 billion, focusing on the development and commercialization of botulinum toxin products and other related therapies.
Operations: Medy-Tox generates revenue primarily from its biotechnology segment, amounting to ₩234.63 billion. The company focuses on the development and commercialization of botulinum toxin products and related therapies within this sector.
Medy-Tox, a standout in the biotech sector, showcases impressive financial agility with earnings growth of 296.5% over the past year, significantly outpacing its industry's average of 39.9%. This surge is underlined by a robust annual earnings forecast set to climb by 49% annually. Despite facing challenges such as a substantial one-off loss of ₩8.2B last year, the company's revenue growth remains vigorous at 15.7% per year, surpassing Korea's market average of 11.5%. Medy-Tox continues to innovate and expand its market presence, recently declaring a cash dividend which reflects its positive free cash flow and commitment to shareholder returns.
-
Click to explore a detailed breakdown of our findings in Medy-Tox's health report.
-
Examine Medy-Tox's past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Unimicron Technology Corp. specializes in the development, manufacturing, processing, and sale of printed circuit boards and electronic products globally, with a market capitalization of approximately NT$262.16 billion.
